Advanced Health Intelligence Ltd Selected as Finalist for Singapore Ministry of Health Project
- AHI selected as a finalist with a chance to win a validation project worth up to SGD $400,000
- AHI's innovative biometric health assessment solution addresses Singapore's healthcare challenges
- AHI's BHA is a comprehensive care model that provides real-time health insights and risk indicators
- None.
Highlights
- Singapore's Centre for Healthcare Innovation and Temasek Foundation has selected AHI as a finalist for Singapore's Healthcare InnoMatch program.
- AHI was one of 163 registrations from 28 countries and selected as one of 7 finalists.
- AHI's final presentation is on September 29 on stage in Singapore, where three winners will be granted a validation project for up to SGD
$400,000 with a Ministry of Health (MOH) cluster.
- Singapore's Healthcare InnoMatch is a platform that seeks to accelerate the adoption of near-market or market-ready healthcare innovations that are fit for mainstream use.
South Perth, Australia--(Newsfile Corp. - September 13, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("Advanced Health Intelligence" or "AHI") is proud to announce its selection from 163 registrations from 28 countries as a finalist in the prestigious 2023 InnoMatch program. Singapore's Healthcare InnoMatch is a platform that seeks to accelerate the adoption of near-market or market-ready healthcare innovations that are fit for mainstream use to bridge the last mile from innovation to adoption at speed at scale. The event is scheduled for September 29, 2023.
This esteemed program is supported by key healthcare organisations in Singapore, including the Singapore National Healthcare Group (NHG), the Singapore National University Health Systems (NUHS), and SingHealth. Singapore's Ministry of Health established its 'Healthier SG' initiative, a long-term, multi-year effort involving substantial financial commitment. The initial setup costs for the program are estimated at S
A total of 163 participants from 28 different countries registered for Healthcare InnoMatch in 2023. Following a thorough evaluation process by Cluster Innovation Teams, Synapxe, and Temasek Foundation, 7 of the applicants have been selected as finalists and AHI are proud to announce that AHI is one of the seven selected finalists in this prestigious program. The Finale is scheduled for September 29, 2023, the event will allow AHI to present its ground-breaking biometric health assessment (BHA) solution live on stage, showcasing how it effectively addresses the pressing challenges that Singapore faces across its aging population. Three finalists will be granted a contract with a Ministry of Health cluster to the value of up to SGD
Reshaping Preventive Care for a Healthier Population: The landscape of healthcare is evolving rapidly, shifting the focus from healthcare to holistic health, from patients to individuals, and from clinical facilities to community-based care. While the acute care sector has reached maturity and stability, the population health and aged care systems are still developing. In alignment with this paradigm shift, Healthcare InnoMatch aims to spotlight the importance of promoting good health and preventive care beyond the confines of hospitals, extending its reach to encompass the broader community.
Problem Statement: The core challenge addressed by Healthcare InnoMatch is how to harness disruptive innovations to assist not only the healthy population but also those at risk or dealing with illnesses. The goal is to enable comprehensive care models that combat increasing rates of chronic disease and address concerns surrounding an aging population by promoting accessible healthcare options and increasing health literacy.
AHI's Innovative Solution: AHI has been selected as a finalist in recognition of its innovative approach to addressing these critical challenges. The Company's solution leverages cutting-edge technology to deliver convenient real-time health insights to support data-driven preventative care to reshape preventive care, ultimately contributing to the establishment of a healthier population. AHI's live presentation on September 29, 2023, will provide a comprehensive overview of its solution and demonstrate how it aligns with the goals and objectives outlined by Healthcare InnoMatch.
AHI is honoured to have this opportunity to contribute to the ongoing transformation of healthcare, and it looks forward to sharing its vision and solution with the esteemed audience at the 2023 InnoMatch Awards. With the backing of esteemed institutions like the Singapore Centre for Healthcare Innovation, Singapore National Healthcare Group (NHG), Singapore National University Health Systems (NUHS), and SingHealth, the Company remains committed to advancing the field of population health and preventive care, striving to make a positive and lasting impact on the well-being of individuals and communities.
Scott Montgomery, CEO of AHI, said:
"I am thrilled AHI is a finalist in the prestigious 2023 InnoMatch Awards, presented by the Singapore Centre for Healthcare Innovation and supported by Singapore's leading healthcare organisations. I will be taking the stage representing our entire team's efforts on September 29 to showcase our ground-breaking Biometric Health Assessment (BHA), an innovation that is not only cutting-edge but proprietary to AHI.
While we are confident that our approach can help address some of Singapore's urgent healthcare challenges alone, we look forward to sharing the stage with other pioneering organisations. Should we win, this will be the first government deployment for AHI and sets the scene for other forward-thinking governments around the world."
AHI's Unique Position: Introducing the AHI BHA Solution
In response to the problem statement outlined by Healthcare InnoMatch, AHI introduced its Biometric Health Assessment (BHA), a ground-breaking solution uniquely poised to address the myriad of challenges faced in healthcare and well-being. BHA represents a fusion of machine learning trained from peer-reviewed scientific risk classifications and markers combined with real-world clinical data. This is designed to work towards the common goals of population health improvement and early identification of chronic diseases.
Addressing the Comprehensive Care Model: AHI's BHA is not merely a technological solution; it's an integral part of a comprehensive care model that healthcare and social service providers can quickly adopt.
With the BHA's real-time multi-tiered assessment, healthcare providers can obtain estimates of essential vitals, biomarkers and risk indicators without physical examination, enabling immediate and informed care in both virtual and traditional environments. Whether it's a primary care consultation or triage, BHA's intuitive insights can guide healthcare professionals in remote settings, thereby wholly aligning with the objectives of Healthcare InnoMatch.
Robust Clinical Evidence and Data-Driven: To meet the stringent criteria of Healthcare InnoMatch, AHI's BHA has undergone rigorous testing by our Medical and Labs team. It incorporates robust clinical evidence and is calibrated using real-world data, ensuring that the risks identified are robust and can be trusted while being innovative and efficacious. Our research partnerships with academic and clinical organisations provide a continuous feedback loop, allowing the BHA to evolve and improve over time.
Versatility Across Diverse Health Contexts: Elevating Population Care Through BHA's Multifaceted Approach; The BHA's inherent versatility positions it as a transformative force in healthcare, making it particularly suited for broad-scope population care initiatives such as the reasoning behind InnoMatch 2023.
By seamlessly transmitting crucial data to healthcare providers through an individual's smartphone, The BHA revolutionises the way care strategies are designed and implemented. This technology aids clinicians in crafting targeted interventions for chronic conditions, thus aligning perfectly with the fundamental objectives behind InnoMatch's call for innovation.
The BHA offers a comprehensive evaluation that extends beyond medical disease risk criteria to incorporate psychological dimensions, establishing it as an integrative preventive care and disease management tool.
AHI's BHA is perfectly poised to help achieve the goals set by Healthcare InnoMatch by delivering comprehensive, personalised, and evidence-based care solutions. AHI looks forward to the opportunity to demonstrate the transformative capabilities of BHA at the 2023 InnoMatch Awards, further contributing to the advancement of population health and well-being.
The final event for Healthcare InnoMatch 2023 is scheduled for September 29, 2023, from 9:00 AM to 1:30 PM SGT at the Centre for Healthcare Innovation Level 4 Auditorium in Singapore. This event will feature presentations by the seven finalists, including AHI, showcasing their innovative biometric health assessment solution to transform healthcare and promote sustainable, person-centric care models in the community.
*The Board of Advanced Health Intelligence Ltd has approved this announcement.
For more information, contact:
Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech
Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech
About Advanced Health Intelligence Ltd
Advanced Health Intelligence Ltd ('AHI') delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.
Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:
- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
- On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.
Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.
With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.
For more information, please visit: www.ahi.tech.
Cautionary Note Regarding Forward-Looking Statements:
This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.
The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavorable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.
The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/180474
